Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM41 with or without vitamin D3 for birch pollen allergic rhinitis
NL-OMON45256Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of BM41 and vitamin d in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Treatment-related systemic reactions. Planned start Apr 2017; status: withdrawn.
02
Drugs
BM41vitamin d
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON45256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45256.